Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with confirmed or suspected clear cell Renal cell carcinoma;~* 68Ga-P16-093 18F-FDG PET/CT within a week;~* signed written consent.~Exclusion Criteria:~* pregnancy;~* breastfeeding;~* known allergy against PSMA;~* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 68Ga-P16-093 and 18F-FDG PET/ CT scan (Type: EXPERIMENTAL): Within 1 week, each patient underwent PET/CT scan after intravenous administration of 68Ga-P16-093 and 18F-FDG, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).